Selvigaltin (GB1211), an orally offered small molecule galectin-3 inhibitor made being a therapy for liver fibrosis and cirrhosis, was evaluated to evaluate the impact of hepatic impairment on its pharmacokinetics and safety to deal with regulatory requirements. Desk four Statistical assessment of dose proportionality of your pharmacokinetic parameters of GB1211 https://mariet009kvf3.bloggerbags.com/profile